Brain Atrophy Assessment

This lecture offers an in-depth exploration of using brain atrophy measurements as a biomarker for Multiple Sclerosis (MS) progression. The speaker clarifies the conceptual distinction between "brain volume loss" (measured in vivo via MRI) and pathological "atrophy," while emphasizing that atrophy occurs from the earliest stages of MS and correlates significantly with long-term disability and cognitive decline. A key portion of the talk presents findings from large multi-center studies, confirming that deep gray matter atrophy is a particularly strong predictor of future progression in EDSS (disability). Furthermore, the video details a Delphi panel study conducted with neurologists and radiologists to identify barriers to adopting quantitative brain atrophy reports in clinical practice, highlighting the need for real-time, EHR-integrated, and affordable automated tools that ultimately save clinicians time.

Learning objectives

By the end of this lecture, students will be able to:

• Understand why MRI-based volume change is a proxy for, rather than a direct pathological proof of, irreversible tissue atrophy 
• Recognize deep gray matter, cortex, and white matter atrophy as superior predictors of clinical progression compared to traditional lesion counting.
• Learn how in vivo MRI volumetric findings have been validated against postmortem histological studies (e.g., neuronal density/size)
• Identify the current hurdles to implementing quantitative (Q) reports in the clinic, including high costs, software integration difficulties, and a lack of training 
• Understand the necessity of multi-stakeholder collaboration (developers, clinicians, hospitals) to standardize automated pipelines for routine clinical care